scholarly journals Drinking Goals and Their Association With Treatment Retention and Treatment Outcomes Among Clients in Outpatient Alcohol Treatment

2016 ◽  
Vol 52 (3) ◽  
pp. 313-321 ◽  
Author(s):  
Severin Haug ◽  
Peter Eggli ◽  
Michael P. Schaub
2007 ◽  
Vol 25 (3) ◽  
pp. 67-86 ◽  
Author(s):  
Janice L. Pringle ◽  
Nicholas P. Emptage ◽  
Victor Barbetti

2017 ◽  
Vol 22 (6) ◽  
pp. 643-647 ◽  
Author(s):  
Claire E. Blevins ◽  
Ana M. Abrantes ◽  
Megan E. Kurth ◽  
Alan L. Gordon ◽  
Michael D. Stein

2011 ◽  
Vol 10 (1) ◽  
pp. 6-13
Author(s):  
Nataliya Vlasova ◽  
Joseph E. Schumacher ◽  
Oksana Oryschhuk ◽  
Kostyantyn V. Dumchev ◽  
Pavel Slobodyanyuk ◽  
...  

1995 ◽  
Vol 26 (4) ◽  
pp. 643-669 ◽  
Author(s):  
Mark B. Sobell ◽  
Linda C. Sobell ◽  
Douglas R. Gavin

2015 ◽  
Vol 83 (6) ◽  
pp. 1044-1057 ◽  
Author(s):  
Katie Witkiewitz ◽  
Elizabeth McCallion ◽  
Kevin E. Vowles ◽  
Megan Kirouac ◽  
Tessa Frohe ◽  
...  

2018 ◽  
Vol 78 (2) ◽  
pp. 192-200 ◽  
Author(s):  
Bente Glintborg ◽  
Anne Gitte Loft ◽  
Emina Omerovic ◽  
Oliver Hendricks ◽  
Asta Linauskas ◽  
...  

ObjectivesReal-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) in 2016. Clinical characteristics and treatment outcomes were studied in ETA-treated patients, who switched to SB4 (switchers) or maintained ETA (non-switchers). Retention rates were compared with that of a historic cohort of ETA-treated patients. Switchers who resumed ETA treatment (back-switchers) were characterised.MethodsObservational cohort study based on the DANBIO registry. Treatment retention was explored by Kaplan-Meier plots and Cox regression (crude, adjusted).Results1621 (79%) of 2061 ETA-treated patients switched to SB4. Disease activity was unchanged 3 months’ preswitch/postswitch. Non-switchers often received 25 mg ETA (ETA 25 mg pens/syringes and powder solution were still available). One-year adjusted retention rates were: non-switchers: 77% (95% CI: 72% to 82%)/switchers: 83% (79% to 87%)/historic cohort: 90% (88% to 92%). Patients not in remission had lower retention rates than patients in remission, both in switchers (crude HR 1.7 (1.3 to 2.2)) and non-switchers (2.4 (1.7 to 3.6)). During follow-up, 120 patients (7% of switchers) back-switched to ETA. Back-switchers’ clinical characteristics were similar to switchers, and reasons for SB4 withdrawal were mainly subjective.ConclusionSeventy-nine per cent of patients switched from ETA to SB4. After 1 year, adjusted treatment retention rates were lower in switchers versus the historic ETA cohort, but higher than in non-switchers. Withdrawal was more common in patients not in remission. The results suggest that switch outcomes in routine care are affected by patient-related factors and non-specific drug effects.


2016 ◽  
Vol 52 (1) ◽  
pp. 72-79 ◽  
Author(s):  
Kelly E. Dunn ◽  
Joseph A. Harrison ◽  
Jeannie-Marie Leoutsakos ◽  
Dingfen Han ◽  
Eric C. Strain

2004 ◽  
Vol 28 (Supplement) ◽  
pp. 86A
Author(s):  
Nick Heather ◽  
Alex Copello ◽  
Christine Godfrey ◽  
Ray Hodgson ◽  
Jim Orford ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document